glp-1 agonist consultation process receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease Outpatient Sedation Basics for Patients

2017, p

Long-term safety data in the pediatric population is still limited, and ongoing surveillance is crucial to identify potential long-term effects on growth and development

Tirzepatide was approved in 2022

Today, the landscape of GLP-1 therapy is broad

Potential advantages Generally simpler anatomy than gastric bypass No intestinal rerouting Strong option for many first-time bariatric surgery patients Can be a good fit for patients who want a restrictive/metabolic procedure Usually avoids the malabsorption component of bypass Important considerations May worsen or trigger acid reflux in some patients May not be the best option for severe GERD or Barretts esophagus Requires lifelong attention to portion size, protein, vitamins, and habits Some patients may need revision later if reflux or weight regain occurs Gastric Bypass Also called Roux-en-Y gastric bypass Gastric bypass creates a small stomach pouch and reroutes part of the small intestine

Key Difference: Tirzepatide (Mounjaro/Zepbound): Dual GIP/GLP-1 agonist Semaglutide (Wegovy/Ozempic): GLP-1 agonist only Effectiveness Difference: Tirzepatide: 15-22% average body weight loss Semaglutide: 10-15% average body weight loss Semaglutide is less potent but still highly effective and significantly more affordable than brand-name tirzepatide